Moderna, Pfizer, and the mRNA Precedent

In the AI Story

The mRNA research program was sustained through decades when commercial prospects appeared negligible. Karikó's early work — later recognized with the 2023 Nobel Prize in Physiology or Medicine — was conducted on modest academic salary while the private sector considered mRNA therapeutics a research dead end. The scientific workforce was trained in publicly funded graduate programs. The clinical trial infrastructure that eventually enabled rapid COVID vaccine development was publicly funded. The Operation Warp Speed program provided Moderna with nearly a billion dollars in federal funding and Pfizer with a two-billion-dollar advance purchase commitment, eliminating commercial risk during development.

The returns distributed entirely to private shareholders. Moderna's COVID-19 vaccine revenue exceeded thirty-six billion dollars in the first two years. Pfizer's exceeded the same. The NIH received conventional licensing fees — a fraction of one percent of the commercial returns. The specific mechanism for public return that would have enabled proportionate participation — equity stakes in companies receiving Operation Warp Speed funding, royalty streams conditional on pricing, windfall taxation of pandemic profits — did not exist in the institutional architecture.

The political response was inadequate. Temporary intellectual property waivers arrived too late and were implemented too narrowly to address the structural pattern. The institutional architecture was not redesigned. The pattern continues: the current commercialization of publicly funded AI research is following the mRNA template with even larger asymmetries and faster timelines.

The AI precedent is instructive because it shows the pattern operating at a scale where the distributional consequences became politically visible — pandemic profits during a public health emergency provoked unusual scrutiny of the public-private arrangement. The AI transition is producing similar scale of returns but with less political visibility, because the public investment in AI research, sustained through two AI winters over five decades, is less recent and less salient than the mRNA investment sustained through the COVID emergency.

Origin

The mRNA research program has roots in foundational work at the University of Pennsylvania in the 1980s and 1990s. Karikó's collaboration with Drew Weissman on modified nucleosides, published in 2005 after years of rejection from major journals, provided the breakthrough that eventually enabled commercial application. The private-sector interest developed primarily after 2010, with Moderna's founding in 2010 and BioNTech's intensified focus on the platform.

The COVID-19 pandemic compressed the commercialization timeline into months rather than years, making the public-private arrangement visible in ways that slower commercialization would have obscured. The resulting public debate produced proposals for institutional reform — equity stakes, conditional pricing, windfall taxation — that remained largely unimplemented.

Key Ideas

Thirty years of patient public investment. Research the private sector considered commercially worthless for decades.

Seventy billion in two years. Commercial returns concentrated rapidly during the pandemic.

Zero direct public participation. Conventional licensing fees captured a fraction of one percent of commercial returns.

Template for AI. The mRNA pattern is the structural template the AI transition is reproducing at larger scale.

Inadequate political response. The pandemic's visibility did not produce institutional redesign; the pattern continues.

Debates & Critiques

Defenders of the pharmaceutical arrangement argue that private firms took risks in manufacturing scale-up and regulatory approval that deserve disproportionate reward. Critics respond that the scale-up occurred under government contract with advance purchase commitments that eliminated commercial risk, and that the foundational scientific risk was borne by public investment over decades.